Selskabets formål er at drive handel, derunder import og eksport samt agenturvirksomhed med kemiske og pharmaceutiske produkter, medicinalvarer, artikler til sådanne frembringelser.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 309 mio. | 10.9 mio. | 70.4 mio. | 32 mio. | 15 | |
CVR: 20601116
Secondary names: ERCOPHARM A/S
Companies in the same industry and area
CVR 41722460
CVR 39371049
CVR 39503778
CVR 40873309
CVR 31774284
Compared to 406 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
The financial health of ORION PHARMA A/S appears stable, with a notable increase in revenue and profit in 2024, reaching 309 million DKK and 10.9 million DKK, respectively. Over the past four years, revenue has shown a growth trend, rising from 214 million DKK in 2022 to 309 million DKK in 2024, while profit has also improved from 4.5 million DKK in 2021 to nearly 11 million DKK in 2024. However, equity has decreased from 51.7 million DKK in 2023 to 32 million DKK in 2024, raising concerns about the company's financial stability. Despite these challenges, ORION PHARMA maintains a solid position within the pharmaceutical wholesale industry, leveraging its growing revenue stream to enhance profitability.
AI-generated summary
companydata.dk